We wanted to make you aware of a new Phase 2b Clinical Study with a Combination Immunotherapy for Newly Diagnosed Patients with Glioblastoma (GBM).
Imvax is a clinical-stage biotechnology company with a unique platform technology, Goldspire™, focused on delivering personalized, whole tumor-derived immunotherapies across a range of solid tumors. Imvax’s most advanced program, IGV-001, is currently being evaluated in a Phase 2b clinical trial in newly diagnosed glioblastoma patients (NCT04485949). Imvax’s portfolio also includes several other programs designed to stimulate a patient’s immune system against the entire antigen signature of their tumor. Imvax is headquartered in Philadelphia, PA.
For additional information on the Imvax Immunotherapy Clinical Study, please visit www.imvax.com and follow @imvax_inc on Twitter and LinkedIn, contact Madhavi Diwanji at 267-900-4110 or at email@example.com OR please contact www.EndBrainCancer.org, fill out our short “Advocacy & Patient Inquiry Form” on our website, or call EBCI’s Program & Trial/Study Manager at 425-436-8688 or email us at WeCare@EndBrainCancer.org. We are here to help.
Dellann Elliott Mydland
President & Board Chair
The EndBrainCancer Initiative | Chris Elliott Fund